Lymphoma Management Updates for 2021 - SPOC

This lecture will review some of the new drugs recently FDA approved for management of lymphoma such as CAR-T therapy for relapsed/refractory Mantle Cell Lymphoma or follicular lymphoma. For rel/ref DLBCL, polatuzumab vedotin in combination with bendamustine and rituximab as well as tafasitamab plus lenalidomide have been approved in recent years. We will review the data and outcomes.

Target Audience

These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, registered nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, allied health personnel, and others who are interested in care for patients and survivors in North Carolina.

Learning Objectives

  • Identify new indications for CAR-T therapy: rel/ref Mantle cell and follicular lymphoma
  • Discuss mechanism of action of polatuzumab vedotin
  • Recall long-term data for use of tafasitimab + lenalidomide in rel/ref DLBCL

 

Taking the Course

To continue, click the button Take Course.

If you do not see the button, please ensure that you are logged in. If you are logged in and still don't see the button, please contact us at [email protected] or (919) 445–1000.

Course summary
Available credit: 
  • 1.00 Participation
Course opens: 
02/17/2022
Course expires: 
12/31/2028
Photo of Anne W. Beaven, MD 

Anne W. Beaven, MD

Associate Professor of Medicine
Vice Chief of Operations, Division of Hematology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

 

This Non-Credit Course does not have accreditation. It only offers general participation certificates.

Available Credit

  • 1.00 Participation
Please login or register to take this course.